IGC Pharma (IGC) Non-Current Debt (2016 - 2025)
Historic Non-Current Debt for Pharma (IGC) over the last 14 years, with Q3 2025 value amounting to $132000.0.
- Pharma's Non-Current Debt fell 222.22% to $132000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $132000.0, marking a year-over-year decrease of 222.22%. This contributed to the annual value of $134000.0 for FY2025, which is 218.98% down from last year.
- Per Pharma's latest filing, its Non-Current Debt stood at $132000.0 for Q3 2025, which was down 222.22% from $133000.0 recorded in Q2 2025.
- In the past 5 years, Pharma's Non-Current Debt ranged from a high of $276000.0 in Q1 2021 and a low of $132000.0 during Q3 2025
- In the last 5 years, Pharma's Non-Current Debt had a median value of $140000.0 in 2023 and averaged $146473.7.
- Per our database at Business Quant, Pharma's Non-Current Debt tumbled by 7666.67% in 2021 and then tumbled by 208.33% in 2023.
- Pharma's Non-Current Debt (Quarter) stood at $145000.0 in 2021, then dropped by 2.76% to $141000.0 in 2022, then decreased by 2.13% to $138000.0 in 2023, then decreased by 2.9% to $134000.0 in 2024, then fell by 1.49% to $132000.0 in 2025.
- Its Non-Current Debt stands at $132000.0 for Q3 2025, versus $133000.0 for Q2 2025 and $134000.0 for Q1 2025.